Sept. 24, 2026 -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage biopharmaceutical company (2696.HK). Under the agreement, Amberstone will work with Henlius to apply its proprietary T-MATE™ (Tumor Microenvironment Activated ThErapeutics) platform technology to generate preclinical candidates against up to tw

The medtech rumor mill is churning with speculation that GE HealthCare may be in M&A talks with Sofie Biosciences. Citing “people familiar with the matter,” the Financial Times reported that GE HealthCare could pay up to $1 billion for Sofie. Dulles, VA-based Sofie Biosciences develops and delivers molecular diagnostics and therapeutics (theranostics). During Wells Fargo’s annual healthcare conference last week, GE HealthCare CEO Peter Arduini said the company believes there are "some good oppor

– Completion of BLA submission expected in Q4 2026 – Sept. 21, 2026 -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026. "Our team looks forward to completing the ST-920 BLA submission and potentially bringing

Iambic launched a larger version of its Enchant drug-discovery model on Monday alongside a multi-year agreement with AbbVie that will put the technology to work across immunology, neuroscience and oncology. The tie-up adds another large pharma partner to Iambic's portfolio just months after deals with Takeda and Bayer. "The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases. The agreement is consistent with mAbxience's strategy of broadening patient access to high-quality biologic medicines through selected partnerships in global marke

Roche and Dualitas Therapeutics, a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation (I&I) diseases, have announced a research collaboration and license agreement with to advance novel bispecific antibodies for I&I diseases In what is believed to be one of the largest-scale bispecific discovery endeavours, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen over 300,000 novel bispecific combinations to

Partnership combines manufacturing, development and clinical operations expertise to accelerate Investigator-Initiated Trials and clinical execution in China Aug. 16, 2026 -- ProBio, a leading global contract development and manufacturing organization (CDMO) focused on biologics and cell and gene therapies (CGT), today announced a strategic collaboration with Kun Tuo, an IQVIA company and leading clinical research organization (CRO) in China. The partnership aims to accelerate Investigator-Init

Combination creates a scaled U.S. advanced therapies CDMO with broader technical expertise and capabilities from early development through commercial supply. Kincell Bio and Cellipont Bioservices today announced the completion of their merger to form Kincellis Advanced Therapies (Kincellis) , a U.S.-based contract development and manufacturing organization focused on cell therapies and other advanced modalities. Kincellis Advanced Therapies brings together Kincell’s depth in immune-cell techno

Trailblazing approach to leverage learnings from rare POLG disorders to inform development for Parkinson's and other age-related neurological diseases Sept. 15, 2026 -- Mighty Therapeutics (the "Company" or "Mighty"), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, is celebrating World Mitochondrial Disease Awareness Week by announcing today its initiation of a research collaboration wi

GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager (TCE), positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The deal comes two years after GSK paid China’s Chimagen $300 million upfront for a trispecific lupus prospect. Neither party has disclosed the targets of the new candidate, but GSK shed some light on the rationale for the trispecific design. TCEs have shown “transformational efficacy in multiple mye